0.05,X 2 =0.45),and the focus stability ratio were42.5%and32.4%respectively.Compared with the FOLFOX4group,the hospitalization course in capecitabine group is significantly shorter(8.5days vs25.3days,P=0.000)and the total medical cost was significantly lower(5941.7RMB vs13304.6RMB,P=0.001).The cost structure analysis showed that the direct and indirect medical costs of the FOLFOX4group increased more significantly(P=0.001)and the incidence for adverse effects of this group was lower than that of the capecitabine group.CONCLUSION:From the perspective of pharmacoeconomic evaluation,capecitabine is better than FOLFOX4in treating the digestive malignant tumor.

Objective: To observe the safety and clinical efficacy of tumor antigen-pulsed dendritic cell(DC) vaccine in treatment of advanced malignant tumor.Methods: Ninety-one patients with non-small cell lung cancer,colon and rectal cancer,melanoma,renal carcinoma,breast cancer and other malignant tumors were enrolled in this study.All patients met the selecting standard and signed informed consent.Human dendritic cells were obtained from peripheral blood monocytes by culturing them with granulocyte macrophage-colony stimulating factor and interleukin-4.DC vaccine was prepared from tumor antigen pulsed immature dendritic cells in vitro.Patients received the vaccine therapy once every week and one cycle was defined as once every week for 3 weeks.Results: All the patients received 96 cycles of DC vaccine treatment.Symptoms of toxicity included fever,shivering,aching pain of muscle,asthenia,itching,stifle and transient fatigue;most of the symptoms automatically recovered.Clinical efficacy of the treatment was evaluated in 76 patients.Thirty-one of the 76 patients were stable after treatment and 45 were in progressive situation,with the clinical benefiting rate being 40.8%.Eighty-five patients were followed up.The median time for progression was 2.6 months;the overall survival time was 0.9-30.6 months;and the median survival period was 4.5 months,with the one year survival rate being 9.2%.Conclusion: The results suggest that the DC vaccine therapy is well tolerated in treating patients with advanced malignant tumors and has satisfactory clinical benefit;the clinical value of DC vaccine therapy needs to be further observed.

Objective A link between homocysteine (Hcy) and left ventricular ejection fraction(LVEF) emerged from re-cent studies but was yet not explored specifically in type 2 diabetic patients. This study aimed to assess the relationship between LVEF and Hcy in type 2 diabetic patients. Methods A total of 72 type 2 diabetic patients were selected for this study and were divided into two groups (40 examples with coronary heart disease, 32 examples without coronary heart disease) javascript:Serum Hcy,glycosylated hemoglobin,cholesterol(TC) and triglyceride(TG) were analyzed.LVEF was assessed by echocardiography. Results There was no difference in systolic blood pressure, diastolic blood pressure, glycosylated hemoglobin,total cholesterol and triglyceride in two groups of patients (P>0.05);The serum Hcy was obvi-ously higher in type 2 diabetic patients with coronary heart disease compared to those without (P<0.05);Factors signifi-cantly associated with a LVEF<55%were serum Hcy OR=1.211(95%CI 1.041~1.408) in type 2 diabetic patients with coronary heart disease.The serum Hcy had significant negatively correlation with LVEF (r=-0.706,P=0.000) in type 2 diabetic patients with coronary heart disease. Conclusion This study highlights an inverse relationship between Hcy and LVEF in type 2 diabetic patients with coronary artery disease.The serum Hcy is a risk factor associated with a LVEF<55%.